Important safety considerations include a boxed warning for thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), and warnings for pancreatitis, gallbladder disease, acute kidney injury, and severe gastrointestinal disease
There were no significant correlations between changes in CRP with tirzepatide and changes in systolic BP, eGFR or log UACR (Extended Data Table 2)
If you travel with tirzepatide, insulated pouches with ice packs maintain the cold chain
Factors like strength, dosage, method of administration, and other aspects may vary, making a direct comparison between the effects and risk profiles of FDA-approved medications and compounded medications challenging
Treatment starts at a low dose and is gradually increased to improve tolerability